TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating

Moomoo NewsOct 31 08:34 ET · Ratings

H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32

Moomoo NewsOct 30 12:32 ET · Ratings

Leerink Partners Maintains Sagimet Biosciences(SGMT.US) With Buy Rating

Moomoo NewsOct 30 08:33 ET · Ratings

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

GlobeNewswireOct 29 07:00 ET

Express News | Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024

ReutersOct 29 07:00 ET

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting 2024

GlobeNewswireOct 16 07:00 ET